Physician profile
Benjamin Gilbert
NPI 1811930118
$5,267.57
in general payments reported to CMS, 2019-2025
27 companies · $3,213 in 2025
The $3,213 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $271 · 2021: $395 · 2022: $237 · 2023: $355 · 2024: $648 · 2025: $3,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,778 · Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,777.50 |
| Food and Beverage | $1,438.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,144.73 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Glaukos Corporation | $350.14 | 2021-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Alcon Vision LLC | $291.54 | 2020-2025 | Rocklatan, Acrysof Iq Panoptix Uv Iol, Clareon |
| Abbvie INC. | $276.49 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $205.65 | 2019-2021 | |
| Allergan, INC. | $119.98 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $119.64 | 2021-2023 | Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $102.37 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $80.35 | 2021-2023 | Xeomin |
| Maculogix, INC. | $70.02 | 2020-2021 | |
| Dompe US, INC. | $51.40 | 2019-2025 | Oxervate |
| Boston Scientific Corporation | $44.08 | 2024 | Wavewriter Alpha Prime 16 |
| Johnson & Johnson Vision Care, INC. | $43.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $39.38 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $37.56 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $35.48 | 2022-2025 | Scoutpro Osmolarity System |
| Horizon Therapeutics Plc | $33.19 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $28.89 | 2023 | |
| Lkc Technologies, INC. | $24.42 | 2025 | |
| Amgen INC. | $22.75 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $22.12 | 2024 | Tyrvaya |
| Lombart Brothers, INC. | $21.83 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.75 | 2024 | Acthar |
| Thea Pharma INC. | $21.24 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.83 | 2020 | |
| Carl Zeiss Meditec, INC. | $19.80 | 2021 | |
| Biotissue Holdings INC. | $17.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.